Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)

被引：0
|
作者：
Goergen, Ellinor [1 ,2 ]
von Tresckow, Julia [3 ]
Giza, Adam [1 ,2 ]
Robrecht, Sandra [1 ,2 ]
Fink, Anna-Maria [1 ,2 ]
Fischer, Kirsten [1 ,2 ]
Al-Sawaf, Othman [1 ,2 ]
Fuerstenau, Moritz [1 ,2 ]
Simon, Florian [1 ,2 ]
Kutsch, Nadine [1 ,2 ]
Nieper, Pascal [1 ,2 ]
Tausch, Eugen [4 ]
Ritgen, Matthias [5 ]
Boettcher, Sebastian
Kreuzer, Karl-Anton [1 ,2 ]
Stilgenbauer, Stephan [4 ,6 ]
Langerbeins, Petra [1 ,2 ]
Eichhorst, Barbara [1 ,2 ]
Hallek, Michael [1 ,2 ]
Cramer, Paula [1 ,2 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany
[4] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[5] Univ Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany
[6] Univ Rostock, Clin Hematol Oncol & Palliat Med 3, Rostock, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CLL; second primary malignancies; obinutuzumab; ibrutinib; venetoclax; Phase; 2;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-465
引用
收藏
页码：S354 / S355
页数：2
相关论文
共 50 条
  • [1] Second primary malignancies (SPM) in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL Study Group (GCLLSG)
    Fuerstenau, M.
    Stumpf, T.
    Fink, A. -M.
    Robrecht, S.
    Bahlo, J.
    Maurer, C.
    Linde, H.
    Jacobasch, L.
    Doerfel, S.
    Lipke, J.
    Aldaoud, A.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 19 - 19
  • [2] Second Primary Malignancies (SPM) in Chronic Lymphocytic Leukemia (CLL) after First-line Treatment: Results of a Metaanalysis of the German CLL Study Group (GCLLSG)
    Maurer, C.
    Langerbeins, P.
    Cramer, P.
    Bahlo, J.
    Fink, A. M.
    Fischer, K.
    Wendtner, C-M
    Hallek, M.
    Eichhorst, B.
    ONKOLOGIE, 2013, 36 : 221 - 221
  • [3] Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Busch, Raymonde
    Renschler, Jasmin
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael J.
    Fink, Anna-Maria
    Kilp, Julia
    Ritgen, Matthias
    Boettcher, Sebastian
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    BLOOD, 2008, 112 (11) : 128 - 128
  • [4] Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).
    Fischer, Kirsien
    Stilgenbauer, Stephan
    Schweighofer, Carmen D.
    Renschler, Jasmin
    Busch, Raymonde
    Kiehl, Michael
    Balleisen, Leopold
    Eckart, Michael
    Fink, Anna M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Staib, Peter
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 913A - 914A
  • [5] Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)
    Kumar, Vivek
    Ailawadhi, Sikander
    Bojanini, Leyla
    Mehta, Aditya
    Singh, Anshika
    Sher, Taimur
    Roy, Vivek
    Vishnu, Prakash
    Marin-Acevedo, Julian A.
    Alegria, Victoria R.
    Paulus, Aneel
    Aulakh, Sonikpreet
    Iqbal, Madiha
    Manochakian, Rami
    Tan, Winston
    Chanan-Khan, Asher A.
    Ailawadhi, Meghna
    BLOOD, 2018, 132
  • [6] Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Robrecht, Sandra
    Bahlo, Jasmin
    Al-Sawaf, Othman
    Langerbeins, Petra
    Heinz, Werner
    Vehling-Kaiser, Ursula
    Durig, Jan
    Tausch, Eugen
    Hensel, Manfred
    Fink, Anna-Maria
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara F.
    Hallek, Michael J.
    BLOOD, 2017, 130
  • [7] Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Von Tresckow, Julia
    Fink, Anna-Maria
    Braun, Gracia
    Robrecht, Sandra
    Zhang, Can
    Tausch, Eugen
    Mueller, Lothar
    Knauf, Wolfgang
    Al-Sawaf, Othman
    Pelzer, Benedikt
    Langerbeins, Petra
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2020, 136
  • [8] Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Von Tresckow, J.
    Lange, E.
    Kiehl, M.
    Dreyling, M.
    Ritgen, M.
    Duerig, J.
    Tausch, E.
    Schneider, C.
    Stilgenbauer, S.
    Wendtner, C. M.
    Fischer, K.
    Goede, V
    Hallek, M.
    Eichhorst, B.
    LEUKEMIA, 2021, 35 (01) : 169 - 176
  • [9] Targeted agents in chronic lymphocytic leukemia (CLL): data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
    Kutsch, Nadine
    Ligtvoet, Rudy
    Robrecht, Sandra
    Linde, Hartmut
    Illmer, Thomas
    Doerfel, Steffen
    Lipke, Jorg
    Aldaout, Ali
    Schlag, Rudolf
    Dengler, Jolanta
    Al-Sawaf, Othman
    Langerbeins, Petra
    Cramer, Paula
    Eichhorst, Barbara
    Hallek, Michael
    Fischer, Kirsten
    Fink, Anna
    LEUKEMIA & LYMPHOMA, 2023, 64 : S125 - S126
  • [10] Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    O. Al-Sawaf
    S. Robrecht
    J. Bahlo
    A. M. Fink
    P. Cramer
    J. v Tresckow
    E. Lange
    M. Kiehl
    M. Dreyling
    M. Ritgen
    J. Dürig
    E. Tausch
    C. Schneider
    S. Stilgenbauer
    C. M. Wendtner
    K. Fischer
    M. Goede
    B. Hallek
    Leukemia, 2021, 35 : 169 - 176
12345